Evidence map›Paper›PMID 30498242›Full record

ArticleNature communications2018

High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer.

Gloria V Echeverria, Emily Powell, Sahil Seth, Zhongqi Ge, Alessandro Carugo, Christopher Bristow, Michael Peoples, Frederick Robinson, Huan Qiu, Jiansu Shao and 11 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 1 synthesis or guideline pooled it, 141 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Collective migration modes in development, tissue repair and cancer.Nature reviews. Molecular cell biology · 2025
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Patient-Derived Xenografts of Breast Cancer.Advances in experimental medicine and biology · 2025
    Review
  19. Review
  20. Review

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Gloria V EcheverriaDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.
Emily PowellDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.
Sahil SethDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.ORCID http://orcid.org/0000-0003-4579-3959
Zhongqi GeDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.
Alessandro CarugoInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.
Christopher BristowInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.
Michael PeoplesInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.
Frederick RobinsonInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.
Huan QiuDepartment of Integrative Biology and Pharmacology, The University of Texas Health Science Center, Houston, 77030, TX, USA.
Jiansu ShaoDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.
Sabrina L Jeter-JonesDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.
Xiaomei ZhangDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.
Vandhana RamamoorthyInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.
Shirong CaiDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.
Wenhui WuDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, 77030, TX, USA.
Giulio DraettaDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.ORCID http://orcid.org/0000-0001-5225-9610
Stacy L MoulderDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, TX, USA.
William F SymmansDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, 77030, TX, USA.
Jeffrey T ChangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, 77030, TX, USA.
Timothy P HeffernanInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA.
Helen Piwnica-WormsDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77054, TX, USA. hpiwnica-worms@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USThe University of Texas Health Science Center at Houston · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Translational Research in Breast Cancer (SPORE)P50CA186784 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Xiang Zhang · 2014 to 2026
$24.5M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA186784
6 · The paper itself

Abstract

Most triple negative breast cancers (TNBCs) are aggressively metastatic with a high degree of intra-tumoral heterogeneity (ITH), but how ITH contributes to metastasis is unclear. Here, clonal dynamics during metastasis were studied in vivo using two patient-derived xenograft (PDX) models established from the treatment-naive primary breast tumors of TNBC patients diagnosed with synchronous metastasis. Genomic sequencing and high-complexity barcode-mediated clonal tracking reveal robust alterations in clonal architecture between primary tumors and corresponding metastases. Polyclonal seeding and maintenance of heterogeneous populations of low-abundance subclones is observed in each metastasis. However, lung, liver, and brain metastases are enriched for an identical population of high-abundance subclones, demonstrating that primary tumor clones harbor properties enabling them to seed and thrive in multiple organ sites. Further, clones that dominate multi-organ metastases share a genomic lineage. Thus, intrinsic properties of rare primary tumor subclones enable the seeding and colonization of metastases in secondary organs in these models.

Indexed as

AnimalsBrain NeoplasmsDisease Models, AnimalFemaleHumansLiver NeoplasmsLung NeoplasmsMiceMice, SCIDNeoplasm MetastasisTriple Negative Breast NeoplasmsXenograft Model Antitumor Assays

Identifiers

PMID30498242
PMCPMC6265294
OpenAlexW2901738572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.